Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 2,007 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 2,007 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.04, for a total value of $24,164.28. Following the sale, the insider now directly owns 39,601 shares in the company, valued at approximately $476,796.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $0.45 during mid-day trading on Tuesday, reaching $12.02. The company had a trading volume of 1,505,032 shares, compared to its average volume of 943,265. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $18.12. The stock has a market capitalization of $590.80 million, a PE ratio of -4.61 and a beta of 2.06. The stock’s 50 day moving average is $13.66 and its 200-day moving average is $9.79.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The business had revenue of $15.16 million during the quarter, compared to the consensus estimate of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NRIX shares. Royal Bank of Canada raised their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Morgan Stanley raised their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. HC Wainwright dropped their target price on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Robert W. Baird lifted their price objective on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a report on Thursday, April 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $21.33.

Institutional Investors Weigh In On Nurix Therapeutics

Hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC raised its position in Nurix Therapeutics by 23.2% in the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock worth $32,972,000 after purchasing an additional 601,952 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Nurix Therapeutics by 176.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after purchasing an additional 440,112 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Nurix Therapeutics by 48.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after purchasing an additional 184,617 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Nurix Therapeutics by 1,012.4% in the third quarter. GSA Capital Partners LLP now owns 195,420 shares of the company’s stock valued at $1,536,000 after acquiring an additional 177,852 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its stake in Nurix Therapeutics by 192.7% in the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after acquiring an additional 107,719 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.